SGRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SGRY is not a good buy right now for an impatient investor. The stock is still in a clear bearish trend (bearish MA stack and worsening MACD), and there are no Intellectia buy-type signals to override the weak technical setup. While the price is near support and appears short-term oversold, the risk of further downside remains elevated (pattern-based odds skew negative over the next week). Unless you already own it and are willing to tolerate volatility for a rebound, the better call is to avoid new buys today and wait for a trend reversal or a confirmed bounce off support.
Intellectia Proprietary Trading Signals
Trend is bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), which typically signals a sustained downtrend. MACD histogram is -0.0959 and negatively expanding, indicating downside momentum is strengthening rather than stabilizing. RSI_6 at 28.265 suggests the stock is approaching oversold conditions (near-term bounce potential), but oversold can persist in downtrends. Key levels: immediate support S1 ~14.61 (price 14.705 is hovering just above it); if that breaks, next support S2 ~14.117. Resistance is overhead at pivot ~15.408, then R1 ~16.207. The statistical pattern read also leans negative (higher probability of modest declines over 1 week and 1 month), reinforcing that momentum has not turned.
and price sitting just above support (~14.
can create a technical bounce setup.
Latest reported quarter: 2025/Q3. Revenue grew to $821.5M (+6.63% YoY), and gross margin improved to 18.97 (+14.83% YoY), which is constructive on operating efficiency. However, profitability deteriorated: net income fell to -$22.7M (-28.39% YoY) and EPS dropped to -$0.18 (-28% YoY). Overall: top-line growth and margin improvement are positives, but ongoing losses reduce near-term confidence and help explain why the stock is technically weak.
Recent analyst trend is negative on price targets: multiple firms cut targets (e.g., JPMorgan 27->20 Neutral; Barclays 24->18 Equal Weight; Mizuho 28->22 Outperform; UBS 34->29 Buy; Benchmark 35->30 Buy; RBC 35->31 Outperform; Jefferies 30->28 Buy; BofA 28->24 Buy; later Mizuho 22->19 Outperform). Ratings are mixed but still skew to constructive (several Buys/Outperforms remain), while Neutral/Equal Weight voices emphasize payer mix/volume pressure and visibility issues.
Wall Street pros: long-term ASC tailwinds, potential divestitures and deleveraging, and views that prior selloff may be overdone. Wall Street cons: payer mix pressure, volume deceleration, reduced earnings visibility, and guidance-related resets driving target cuts.
